# Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study

> **NCT03152097** · NA · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 13 (actual)

## Conditions studied

- Kidney Diseases
- Cardiovascular Diseases

## Interventions

- **DIETARY_SUPPLEMENT:** Commercially available Diindolylmethane
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03152097
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-30
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-08-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03152097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03152097, "Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03152097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*